Different Topical Dutasteride Formulations 2/27/2023
The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Topical Dutasteride 0.05% With Trichosol In Europe
A user from Ireland is seeking topical dutasteride with trichosol, which is unavailable in Ireland, and is looking for European pharmacies that can provide it. Recommendations include pharmacies in Switzerland, Italy, Belgium, and Bucharest, with mixed reviews about Farmacia Parati in Italy.
community After 6 months of treatment, my hair is growing back.
A 26-year-old man shared his 6-month hair regrowth progress using 0.25% topical finasteride, 5% topical minoxidil, Trichosol, and weekly derma stamping. He plans to start using a lotion with dutasteride and azelaic acid.
community Topical Dutasteride 1% - High dosage?
User asks about two topical dutasteride solutions and wonders if 1% concentration is overkill compared to 0.1%. They also consider trying standard topical dutasteride before using Minoxidil.
community New topical Dutasteride from Moogene will have 20 times better scalp absorption than oral Dutasteride. And much lower system absorption.
A new topical Dutasteride with 20 times better scalp absorption being developed and tested for release in 2023; use of existing drugs, such as Minoxidil and finasteride; and mesotherapy as an alternative hair loss treatment.
community Is Topical Dutasteride best for preventative loss?
The user is considering using topical dutasteride to prevent hair loss progression from Norwood 1 to Norwood 2 at age 25, and is concerned about the long-term effectiveness and potential shedding from the treatment. They are currently using a shampoo with caffeine, rosemary, and saw palmetto, and have noticed hair thinning and changes since age 20.
Related Research
6 / 6 results
research Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Progesterone, and Pyridoxine Hydrochloride in TrichoSolTM, A Natural Vehicle for Hair Solutions.
In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.
research Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss: a prospective cohort study
This study found that metabolic syndrome negatively affected the response to intradermal dutasteride injection in female pattern hair loss, with participants showing reduced terminal hair and increased vellus hair compared to those without the syndrome.
research RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia
This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.
research Comparative efficacy of oral dutasteride and low-, medium-, and high-dose oral minoxidil: a six-month prospective trichoscopic and clinical study
This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.
research Androgenetic, Diffuse and Senescent Alopecia in Men: Practical Evaluation and Management
This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.
research Platelet‐rich plasma with low dose oral minoxidil (1.25mg versus 2.5mg) along with trichoscopic pre‐ and post‐treatment evaluation
This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.